Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Change in Accured Expenses (2022 - 2025)

Core Laboratories (CLB) has 4 years of Change in Accured Expenses data on record, last reported at $1.2 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 147.01% year-over-year to $1.2 million; the TTM value through Sep 2025 reached $2.8 million, down 52.5%, while the annual FY2024 figure was $2.5 million, 774.93% up from the prior year.
  • Change in Accured Expenses reached $1.2 million in Q3 2025 per CLB's latest filing, up from -$30000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $11.1 million in Q4 2022 and bottomed at -$3.3 million in Q3 2022.
  • Average Change in Accured Expenses over 4 years is $904230.8, with a median of -$30000.0 recorded in 2025.
  • The widest YoY moves for Change in Accured Expenses: up 323.82% in 2024, down 349.73% in 2024.
  • A 4-year view of Change in Accured Expenses shows it stood at $11.1 million in 2022, then crashed by 60.7% to $4.4 million in 2023, then plummeted by 77.02% to $1.0 million in 2024, then grew by 20.4% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $1.2 million in Q3 2025, -$30000.0 in Q2 2025, and $617000.0 in Q1 2025.